Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 203 for “"bispecific"”.
-
Enhancement of CD117-Targeted Bispecific T-Cell Engagement by CD33-Targeted Bispecific T-Cell Co-Stimulation in AML
… overall poor clinical outcome. T-cell engaging bispecific antibodies (TCEs), binding to a tumor-associated antigen and to CD3, redirect T-cells to the target-antigen expressing cells in an MHC/TCR-independent fashion. The development of TCEs for clinical application is facing several challenges. …
-
The Construction and Analysis of Bispecific Antibodies
… anti- ovarian carcinoma) to produce functional 'bispecific' antibodies, -that is, antibodies capable of directing cytotoxicity towards ovarian cancer cell targets. The cross-linking of antibodies by chemical means proved to be a difficult task. The cross-linker SMPB, was found to be impractical …
-
Multivalent and bispecific immunostimulatory antibodies for cancer immunotherapy
… tumour microenvironment, we produced a range of bispecific antibodies targeting m4-1BB and B7-H3. In vitro and in vivo assessment identified that a tetravalent bispecific antibody (2x2) format was the most effective. This format was then used to show that anti-m4-1BB x anti-B7-H3 2x2 bispecific …
-
Development of Bispecific Proteins for Applications in Immunotherapy
… garnering attention is the development of bispecifics. These recombinant proteins are designed to harbor two functional domains addressing one or more of the following criteria: improved drug safety and efficacy, bridging and activating immune cells, targeted delivery, or dual signal …
-
Studies on the production and applications of bispecific antibodies
… and optimise the production and application of bispecific antibodies. A bispecific antibody is an immunoglobulin-derived molecule which binds monovalently to two distinct antigens. It can be produced using somatic cell fusion techniques or by chemical m anipulation of the parental immunoglobulin …
-
Bispecific Ligand Conjugate Immunotherapy of Choroid Plexus Brain Tumors
… work may offer insights into the application of bispecific ligand conjugates to the treatment of human cancers. Application of this design includes all tumors that express folate receptors, but additional ligands may be used to target other tumor varieties.
-
The emergence of bispecific antibodies as novel cancer therapeutics
Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new variations of the basic bispecific concept …
-
Radioimmunotargeting of renal cell carcinoma with bispecific monoclonal antibodies
KUN, 08 september 1998
-
Engineered Bispecific Antibodies and Immune Cytokine Mimetics for Therapeutic Applications
… Department. My first project is engineering bispecific antibodies that target IL-6 and IL-8 to synergistically inhibit cancer metastasis. We engineered two bispecific antibody-based constructs that simultaneously block activation of the IL-6 and IL-8 receptors to inhibit tumor metastasis and …
-
TARGETING SHARED CANCER NEOANTIGENS WITH BISPECIFIC T CELL-RETARGETING ANTIBODIES
… anti-CD3 antibody, generating T cell-retargeting bispecific antibodies. These bispecific antibodies were capable of activating T cells in the presence of target cells presenting extremely low antigen levels. They killed tumor cells in vitro and in mice in a fashion exquisitely dependent on the …
-
Bench to bedside: A Bispecific Antibody for treating Brain Tumors
… the pre-clinical and clinical development of a bispecific antibody – EGFRvIII:CD3 bi-scFv – for the treatment of malignant gliomas.</p><p>Chapter 1 reviews current front-line immunotherapy research in the fields of antibodies, including BiTEs and checkpoint inhibitors, and tumor vaccinations, …
-
DESIGN AND DEVELOPMENT OF BISPECIFIC ANTIBODIES FOR HIV-1 RESERVOIR ELIMINATION
… development and preclinical characterization of bispecific antibodies capable of potently and specifically enhancing the elimination of HIV-1-infected CD4+ T cells by cytolytic CTLs and NK cells.
-
Engineering a CD19-Based Bispecific Molecule for CAR T Cell Therapy
… encoding CAR specificity towards a secondary, bispecific molecule. This split-CAR approach has the propensity to improve antigen specificity, resolve antigen loss, afford dose-able T cell activation, and more. However, while many bispecific molecules have been developed, many lack both …
-
Tuning cell fate with a toolbox of DoubleCatcher bispecific binder scaffolds
… in therapeutic discovery and synthetic biology. Bispecific binders, which bind simultaneously to two different targets, are an example of such a tool. Standard approaches for bispecific synthesis are limited by specialised binder formats or lack geometric tunability. Instead, I designed SpyMask: …
-
Improving bispecific antibody production by tweaking cognate heavy-light chain pairing
… of the IgG molecule. One such format is bispecific antibodies, which harbour two different antigen-binding specificities at either end of the Fab arms. Among the many novel uses for this format, is the capability to target two growth factor receptors simultaneously or to target a tumour …
-
Pretargeted Radioimmunotargeting with Bispecific anti-tumor x anti-DTPA(In) Antibodies.
RU Radboud Universiteit Nijmegen, 25 april 2005
-
Bispecific Radioimmunoconjugates for Molecular Imaging and Radioimmunotherapy of HER2 Overexpressing Breast Cancer
… HER2-targeted therapies. The hypothesis was that bispecific radioimmunoconjugates (bsRICs) developed against HER2 and another member of the HER receptor family would be able to successfully target cells expressing one or more receptor for molecular imaging and radioimmunotherapy of BC. Trastuzumab …
-
Bispecific CD33-TIM3 CAR T cells enhance specificity while maintaining efficacy against AML
Background: CD33, a specific antigen prevalent on myeloid cells, is found in 88% of samples from patients with acute myeloid leukemia (AML), highlighting its potential as an immunotherapeutic target. Despite numerous ongoing clinical trials targeting AML, challenges related to CAR T-cell …
-
Leveraging TCR signaling for the design of sensitive bispecific receptors for cancer therapy
… heterogenous tumors compared to monospecific and bispecific CARs. Additionally, I developed a mass cytometry tool to determine similarities and differences in proximal receptor signaling in engineered T cells and understand how improved signaling may impact cell differentiation and function. …
Page 1 of 11